{"title":"急性白血病的长期生存率。22名成年患者存活超过5年。","authors":"S A Evensen, P Stavem","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An intermittent combination chemotherapy program was initiated in 1971-79 in 172 patients, aged 15-59 years, with acute leukemia (131 myelogenous (AML) and 41 lymphoblastic (ALL]. Sixteen patients with AML and 6 with ALL have survived for more than 5 years. These long-term survivors represent 24% of AML and 18% of ALL patients who obtained complete remission. Twelve patients (10 AML and 2 ALL) are in continuous first remission 5.5-13.5 years after diagnosis. Occasional late relapses up to 9 years after diagnosis make it impossible to declare any individual patient cured.</p>","PeriodicalId":7011,"journal":{"name":"Acta medica Scandinavica","volume":"219 1","pages":"79-83"},"PeriodicalIF":0.0000,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term survival in acute leukemia. Twenty-two adult patients surviving for over five years.\",\"authors\":\"S A Evensen, P Stavem\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>An intermittent combination chemotherapy program was initiated in 1971-79 in 172 patients, aged 15-59 years, with acute leukemia (131 myelogenous (AML) and 41 lymphoblastic (ALL]. Sixteen patients with AML and 6 with ALL have survived for more than 5 years. These long-term survivors represent 24% of AML and 18% of ALL patients who obtained complete remission. Twelve patients (10 AML and 2 ALL) are in continuous first remission 5.5-13.5 years after diagnosis. Occasional late relapses up to 9 years after diagnosis make it impossible to declare any individual patient cured.</p>\",\"PeriodicalId\":7011,\"journal\":{\"name\":\"Acta medica Scandinavica\",\"volume\":\"219 1\",\"pages\":\"79-83\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1986-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta medica Scandinavica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Scandinavica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Long-term survival in acute leukemia. Twenty-two adult patients surviving for over five years.
An intermittent combination chemotherapy program was initiated in 1971-79 in 172 patients, aged 15-59 years, with acute leukemia (131 myelogenous (AML) and 41 lymphoblastic (ALL]. Sixteen patients with AML and 6 with ALL have survived for more than 5 years. These long-term survivors represent 24% of AML and 18% of ALL patients who obtained complete remission. Twelve patients (10 AML and 2 ALL) are in continuous first remission 5.5-13.5 years after diagnosis. Occasional late relapses up to 9 years after diagnosis make it impossible to declare any individual patient cured.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
